Update on the Biology and Treatment of Lymphedema

  • Stanley G. RocksonEmail author
Vascular Disease (H Gornik and E Kim, Section Editors)

Opinion statement

The past decade has produced an explosion of insights into lymphatic vascular development and structural biology and, in parallel, into the function of the lymphatics in health and in disease. In lymphedema, there is a spectrum that extends from primary (heritable) to acquired causes of disease. The diagnosis of lymphatic edema implicates a very specific treatment approach that is predicated upon the favorable impact of physiotherapy upon lymph flow and protein clearance from the edematous zones of the body. The recognition of the unique biology that accompanies lymphatic causes of edema has stimulated new research directions that are likely to translate into exciting new pharmacologic and molecular approaches to diagnosis and treatment.


Lymphedema Immune traffic Lymphangiogenesis 



No conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Rockson SG. Lymphedema. Am J Med. 2001;110(4):288–95.PubMedCrossRefGoogle Scholar
  2. 2.
    Rockson SG. How can lymphatic research influence lymphatic education? Lymphat Res Biol. 2004;2(2):67–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Rockson SG, Granger DN, Skeff KM, Chaite W. Lymphatic biology and disease: is it being taught? Who is listening? Lymphat Res Biol. 2004;2(2):86–95.PubMedCrossRefGoogle Scholar
  4. 4.••
    Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52(10):799–806.PubMedCrossRefGoogle Scholar
  5. 5.•
    Norrmen C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123(12):1335–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Rockson SG. The unique biology of lymphatic edema. Lymphat Res Biol. 2009;7(2):97–100.PubMedCrossRefGoogle Scholar
  7. 7.
    Oliver G. Lymphatic vasculature development. Nat Rev Immunol. 2004;4(1):35–45.PubMedCrossRefGoogle Scholar
  8. 8.
    Hodge LM, Downey HF. Lymphatic pump treatment enhances the lymphatic and immune systems. Exp Biol Med (Maywood). 2011;236(10):1109–15.CrossRefGoogle Scholar
  9. 9.•
    Detry B, Bruyere F, Erpicum C, Paupert J, Lamaye F, Maillard C, Lenoir B, Foidart JM, Thiry M, Noel A. Digging deeper into lymphatic vessel formation in vitro and in vivo. BMC Cell Biol. 2011;12:29.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamura K, Rockson SG. Molecular targets for therapeutic lymphangiogenesis in lymphatic dysfunction and disease. Lymphat Res Biol. 2008;6(3–4):181–9.PubMedCrossRefGoogle Scholar
  11. 11.
    An A, Rockson SG. The potential for molecular treatment strategies in lymphatic disease. Lymphat Res Biol. 2004;2(4):173–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrell RE, Kimak MA, Lawrence EC, Finegold DN. Candidate gene analysis in primary lymphedema. Lymphat Res Biol. 2008;6(2):69–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ, Ferrell RE. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol. 2008;6(2):65–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999;177(3):184–7. discussion 188.PubMedCrossRefGoogle Scholar
  15. 15.
    Ridner SH. The psycho-social impact of lymphedema. Lymphat Res Biol. 2009;7(2):109–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Szuba A, Shin WS, Strauss HW, Rockson S. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med. 2003;44(1):43–57.PubMedGoogle Scholar
  17. 17.
    Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;(in press).Google Scholar
  18. 18.
    Tabibiazar R, Cheung L, Han J, Swanson J, Beilhack A, An A, Dadras SS, Rockson N, Joshi S, Wagner R, Rockson SG. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3(7):e254.PubMedCrossRefGoogle Scholar
  19. 19.
    Avraham T, Daluvoy S, Zampell J, Yan A, Haviv YS, Rockson SG, Mehrara BJ. Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. Am J Pathol. 2010;177(6):3202–14.PubMedCrossRefGoogle Scholar
  20. 20.•
    Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, Rockson SG, Mehrara BJ. Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema. Am J Physiol Cell Physiol. May;300(5):C1107–1121. This is an animal study that underscores the importance of tissue injury responses as an integral component of the biology of lymphedema.Google Scholar
  21. 21.
    Beilhack A, Rockson SG. Immune traffic: a functional overview. Lymphat Res Biol. 2003;1(3):219–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson LA, Jackson DG. Cell traffic and the lymphatic endothelium. Ann N Y Acad Sci. 2008;1131:119–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002;21(7):1505–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769–78.PubMedCrossRefGoogle Scholar
  25. 25.
    Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37(10):1072–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Brorson H, Ohlin K, Olsson G, Karlsson M. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol. 2009;7(1).Google Scholar
  27. 27.
    Brorson H, Ohlin K, Olsson G, Langstrom G, Wiklund I, Svensson H. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology. 2006;39(1):8–25.PubMedGoogle Scholar
  28. 28.
    Brorson H. Liposuction in arm lymphedema treatment. Scand J Surg. 2003;92(4):287–95.PubMedGoogle Scholar
  29. 29.
    Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. Plast Reconstr Surg. 1998;102(4):1058–67. discussion 1068.PubMedCrossRefGoogle Scholar
  30. 30.
    Cheung L, Han J, Beilhack A, Joshi S, Wilburn P, Dua A, An A, Rockson SG. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs. 2006;20(6):363–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Schneider M, Ny A, Ruiz de Almodovar C, Carmeliet P. A new mouse model to study acquired lymphedema. PLoS Med. 2006;3(7):e264.PubMedCrossRefGoogle Scholar
  32. 32.
    Jin D, An A, Liu J, Nakamura K, Rockson S. Therapeutic Responses to Exogenous VEGF-C Administration in Experimental Lymphedema: Immunohistochemical and Molecular Characterization Lymphat Res Biol. 2009;7(1).Google Scholar
  33. 33.
    Lahteenvuo M, Honkonen K, Tervala T, Tammela T, Suominen E, Lahteenvuo J, Kholova I, Alitalo K, Yla-Herttuala S, Saaristo A. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 2011;123(6):613–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer. 2006;95(12):1611–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Cornish B. Bioimpedance analysis: scientific background. Lymphat Res Biol Spring. 2006;4(1):47–50.CrossRefGoogle Scholar
  36. 36.
    Ward LC. Bioelectrical impedance analysis: proven utility in lymphedema risk assessment and therapeutic monitoring. Breast Cancer Res Treat. 2006;4(1):51–6.Google Scholar
  37. 37.
    Szuba A, Cooke JP, Yousuf S, Rockson SG. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. Am J Med. 2000;109(4):296–300.PubMedCrossRefGoogle Scholar
  38. 38.
    Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361(7):664–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Szuba A, Razavi M, Rockson SG. Diagnosis and treatment of concomitant venous obstruction in patients with secondary lymphedema. J Vasc Interv Radiol. 2002;13(8):799–803.PubMedCrossRefGoogle Scholar
  40. 40.
    Raju S, Furrh JBt, Neglen P. Diagnosis and treatment of venous lymphedema. 2011; J Vasc Surg. Sep 27 [Epub ahead of print].Google Scholar
  41. 41.
    Damstra RJ, Voesten HG, van Schelven WD, van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat. 2009;113(2):199–206.PubMedCrossRefGoogle Scholar
  42. 42.
    Weiss M, Baumeister RG, Hahn K. Dynamic lymph flow imaging in patients with oedema of the lower limb for evaluation of the functional outcome after autologous lymph vessel transplantation: an 8-year follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(2):202–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphatic-venous microsurgery. World J Surg. 2004;28(6):609–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006;243(3):313–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Brorson H, Svensson H. Complete reduction of lymphoedema of the arm by liposuction after breast cancer. Scand J Plast Reconstr Surg Hand Surg. 1997;31(2):137–43.PubMedCrossRefGoogle Scholar
  46. 46.
    McGeown JG, McHale NG, Thornbury KD. Effects of varying patterns of external compression on lymph flow in the hindlimb of the anaesthetized sheep. J Physiol. 1988;397:449–57.PubMedGoogle Scholar
  47. 47.
    Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer. 2002;95(11):2260–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Wilburn O, Wilburn P, Rockson SG. A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412]. BMC Cancer. 2006;6:84.PubMedCrossRefGoogle Scholar
  49. 49.
    Rockson SG. Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. Vasc Med. 2010;15(3):223–31.PubMedCrossRefGoogle Scholar
  50. 50.
    Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98(22):12677–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000;25(2):153–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome [in process citation]. Am J Hum Genet. 2000;67(6):1382–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet. 2003;72(6):1470–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Stanford Center for Lymphatic and Venous Disorders, Division of Cardiovascular MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations